Journal
THERANOSTICS
Volume 11, Issue 8, Pages 3565-3579Publisher
IVYSPRING INT PUBL
DOI: 10.7150/thno.54343
Keywords
PCNSL; immune contexture; bioinformatics; immunotherapy; cellular interactions
Categories
Funding
- GIRCI SOOM [API-K 2016-811-DRC-AC]
- ARC PJA [20141201975]
- Labex EpiGenMed [ANR 10-LABX-0012]
Ask authors/readers for more resources
The study identified three immune subtypes of PCNSL: immune-rich, poor, and intermediate. Better survival was associated with the immune-rich subtype, while worse survival was linked to the immune-poor subtype. HLA down-modulation was correlated with poorer survival, and TIM-3 protein could be a potential target for future therapeutic development.
Rationale: Primary central nervous system diffuse large B-cell lymphoma (PCNSL) is a rare and aggressive entity that resides in an immune-privileged site. The tumor microenvironment (TME) and the disruption of the immune surveillance influence lymphoma pathogenesis and immunotherapy resistance. Despite growing knowledge on heterogeneous therapeutic responses, no comprehensive description of the PCNSL TME is available. We hence investigated the immune subtypes of PCNSL and their association with molecular signaling and survival. Methods: Analysis of PCNSL transcriptomes (sequencing, n = 20; microarrays, n = 34). Integrated correlation analysis and signaling pathway topology enabled us to infer intercellular interactions. Immunohistopathology and digital imaging were used to validate bioinformatic results. Results: Transcriptomics revealed three immune subtypes: immune-rich, poor, and intermediate. The immune-rich subtype was associated to better survival and characterized by hyper-activation of STAT3 signaling and inflammatory signaling, e.g., IFNy and TNF-a, resembling the hot subtype described in primary testicular lymphoma and solid cancer. WNT/P-catenin, HIPPO, and NOTCH signaling were hyper-activated in the immune-poor subtype. HLA down-modulation was clearly associated with a low or intermediate immune infiltration and the absence of T-cell activation. Moreover, HLA class I down-regulation was also correlated with worse survival with implications on immune-intermediate PCNSL that frequently feature reduced HLA expression. A ligand-receptor intercellular network revealed high expression of two immune checkpoints, i.e., CTLA-4/CD86 and TIM-3/LAGLS9. TIM-3 and galectin-9 proteins were clearly upregulated in PCNSL. Conclusion: Altogether, our study reveals that patient stratification according to immune subtypes, HLA status, and immune checkpoint molecule quantification should be considered prior to immune checkpoint inhibitor therapy. Moreover, TIM-3 protein should be considered an axis for future therapeutic development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available